Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2024 | Story Leonie Bolleurs | Photo SUPPLIED
Dr Lucas Erasmus
Dr Lucas Erasmus, Junior Researcher in the Department of Physics, has just returned from Belgium where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

“I like taking what I have learned from literature and going to the laboratory to test it. Sometimes the results surprise me, leading to additional experiments or refining. This process could continue for several months and even years, with me slowly building the puzzle. And finally, one day, all the pieces come together, and everything becomes very clear to me as a physicist. And if I am lucky, I will have the privilege of knowing a secret about nature that nobody else has known up to this point. However, as an innovator, I am tasked with using this new knowledge to develop ways to manipulate nature to deliver a helpful device.”

These are the thoughts of Dr Lucas Erasmus, Junior Researcher in the Department of Physics at the University of the Free State (UFS), who has just returned from Ghent, Belgium, where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

The research project is part of a bilateral collaboration between the Department of Physics at the UFS and the Department of Solid State Sciences at Ghent University. In this study, the strengths, experience, and resources of both research groups – experienced in developing luminescent materials for various applications – are used to ensure a stronger final product. To meet the requirements stipulated in the cooperation agreement between the two institutions for the joint supervision and certification of Dr Erasmus’ doctoral studies, research was conducted both at the UFS and at Ghent University.

Dr Erasmus’ research is significant in the light of rising energy prices, energy scarcity, and the pursuit of a carbon-free society, where there are strong incentives to develop new and renewable energy sources.

Combining windows and solar cells increase their relevancy in many applications

He says that although solar panels play an essential role in renewable energy – since they provide a route to directly convert solar radiation into electricity – there are limitations to installing conventional panels, which are bulky, rigid, and opaque. He believes that combining windows and solar cells could increase their relevance in the built environment, agricultural sector, and modern consumer electronics.

Explaining about the luminescent solar concentrator (LSC) in his study, he states that it is a device used as a large-area solar radiation collector that converts and emits radiation. The emitted radiation is directed to photovoltaic cells located in the small side area of the device. According to him, a basic LSC consists of a transparent waveguide with an embedded luminescent material and a strategically placed photovoltaic cell on the edge.

Dr Erasmus continues, “The large area of the waveguide collects a portion of the solar radiation, while the luminescent material absorbs the energy and downshifts it to longer wavelengths. Internal reflection directs the emitted photons towards smaller areas on the sides where the photovoltaic cells are used to convert the concentrated light into electricity.”

In his view, creating a large and efficient LSC is a challenging endeavour that requires an in-depth study of multiple domains. “This includes developing and optimising the luminescent material, studying its behaviour and the characteristics of the waveguide, and finally adding these two components and developing, characterising, and simulating the hybrid device,” he remarks.

“While the current prototype we have developed delivers good results, it is still far from perfect and not commercially viable,” he says, stating that this study could, however, serve as a guide for future researchers interested in developing LCSs. Dr Erasmus believes the underlying science behind the results contributes to a general understanding of the materials, making this study valuable to other fields and contributing to the larger body of science. At the end of the study, he also makes some recommendations for future research in this field. 

Study a reflection of theoretical knowledge and a practical system

The public defence consisted of both an internal and an external defence. The internal defence took place in January at the UFS between Dr Erasmus and the examination committee. The external defence occurred at Ghent University and was also open to the broader public. Also present at this event in Belgium were colleagues from the UFS – Prof David Motaung, an examiner; Prof Koos Terblans, co-supervisor; and Prof Hendrik Swart, supervisor for the PhD thesis.

Dr Erasmus’ experience of the oral examination was that the examiners were primarily positive in their critique but also thorough in their questioning. According to him, some of their remarks pointed out that they were impressed with the meticulous planning, execution, and interpretation of the experimental results and that the researchers involved ensured that any parameter that might have influenced the device was maximised. “Moreover, they liked the fact that I went all the way from theoretical knowledge to a practical system. The examiners also noted that the study compares well with the current state-of-the-art research in the field,” adds Dr Erasmus.

He says that having the public defence in Belgium was a once-in-a-lifetime experience, allowing him to interact and deliberate directly with the examiners and communicate their findings and conclusions to the broader public. Dr Erasmus hopes that this will lead to stronger collaboration and better public sentiment toward spending funding for scientific projects.

For future steps, he states, the research group involved in the project plans to continue this research by further increasing the device's efficiency. “To this end, we have already developed another luminescent material that can address some of the challenges we encountered while developing the first prototype device. This forms part of the work that Johané Odendaal is doing in her master’s degree, of which I am a co-supervisor. We also plan to enlarge the scope of our research to consider the challenges that are currently hampering the next generation of photovoltaic cells and to find ways in which we could address these issues,” comments Dr Erasmus.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept